In Brief

Hi-Tech OTCs up slightly in fiscal 2013; Pharmstandard spins off OTC unit; Nu Skin raises estimates; infant formula makers respond to China inquiry; Pennsylvania joins NPLEx; and Everett alleges Acella infringes in prenatals.

The strong performances of Mag-Ox magnesium supplements and Sinus Buster nasal spray highlight Hi-Tech Pharmacal Co. Inc.’s OTC product division in fiscal 2013, as the division’s sales increased 2.7% to $17.7 million. The OTC unit’s fourth-quarter performance was down, as lower sales of Diabetic Tussin led to a 6.7% drop to $4.9 million. During a July 9 call, executives said the Amityville, N.Y., firm expects advertising and promotion spending to drive double-digit OTC sales growth this year, along with larger gross margins due to discontinuation of pricing promotions. For Hi-Tech’s full-year – ended April 30 – net sales were virtually flat at $232.4 million, with net income down 66.4% to $16.3 million. The firm absorbed a $15.5 million settlement charge related to a Texas investigation into drug pricing, plus $700,000 to settle a class action over Nasal Ease advertising.

Moscow-based Pharmstandard OJSC plans to spin off its branded OTC drug business into an independent, fully operational company by the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

33 States Agree To Standardized Access Policies In Medicaid Sickle Cell Payment Demo

 

States also agreed to fund patient travel to specialized treatment centers as part of their participation in the Medicaid demo of CMS-negotiated outcomes-based contracts for Vertex/CRISPR's Casgevy and bluebird bio's Lyfgenia.

Part B Negotiation Proposal Would Lower Prices In MA, Private Plans Too, Stakeholders Complain

 
• By 

The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches.

‘Missed Opportunity’: GSK Failed To Optimize Blenrep Dosage, US FDA Panel Says

 
• By 

The Oncologic Drugs Advisory Committee said the benefit-risk of belantamab mafoditin for two second-line multiple myeloma indications is not favorable at the proposed dosages and raised concerns about applicability of trial results to US patients.

US FDA’s Second Half 2025 User Fee Goals Swing Toward Respiratory Disease

 

The 43 novel agents with user fee goal dates in the remainder of 2025 have fewer oncologics and infectious disease drugs than the first half of the year

More from North America

Otsuka/Lundbeck’s Rexulti PTSD Claim Will Test US FDA AdComm’s Supportive Evidence Flexibility

 

Rexulti’s post-traumatic stress disorder sNDA tries to make up for a failed Phase III study by placing a Phase II study into a key evidentiary role, raising questions for the July 18 advisory committee meeting about assessing discordant results and post-hoc analyses.

Organ-On-A-Chip: Upcoming US FDA Guidance Could Help Flesh Out ‘Roadmap’

 

The FDA is pushing the use of novel alternatives to animal models, but the Government Accountability Office said sponsors need more clarity and hopes an upcoming guidance will help.

Access Risks Loom For All Drugmakers With Fourth Circuit Mifepristone Decision

 

The FDA law establishing REMS authority does not preempt a West Virginia law that would restrict mifepristone use in the state, an appeals court said, a decision that could have broader ramifications for the agency’s authority to ensure drug access.